Search results for "From ACP Internist"
Regular use of PPIs linked to increased risk of type 2 diabetes
In an analysis of the Nurses' Health and Health Professionals studies, regular users of proton-pump inhibitors (PPIs) had a 24% higher risk of diabetes than nonusers, with longer duration of use associated with greater risk.
https://diabetes.acponline.org/archives/2020/10/09/9.htm
9 Oct 2020
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/11/11/6.htm
11 Nov 2022
Group-based lifestyle intervention reduced risk of type 2 diabetes
Participants in the Norfolk Diabetes Prevention Study who underwent multiple educational group sessions that included 50-minute sessions of supervised physical activity had significantly lower odds of type 2 diabetes during a mean follow-up of two years compared to those who received usual care.
https://diabetes.acponline.org/archives/2020/11/13/9.htm
13 Nov 2020
SGLT-2 inhibitors not associated with increased risk for severe UTIs
An accompanying editorial said that while the study's finding is reassuring, it should be considered with caution, especially since high-risk patients and those with previous urinary tract infections (UTIs) were excluded.
https://diabetes.acponline.org/archives/2019/08/09/7.htm
9 Aug 2019
CGM decreased HbA1c levels, hypoglycemia in patients with type 2 diabetes
Two industry-supported studies of continuous glucose monitoring (CGM) found encouraging results in patients with type 2 diabetes, leading editorialists to call for broadened access to the technology in this population, particularly in primary care.
https://diabetes.acponline.org/archives/2021/06/11/6.htm
11 Jun 2021
Thinking about drug costs and basal insulin in type 2 diabetes
Two articles in the May ACP Internist focused on patients with type 2 diabetes—a cover story explained why and how internists should consider patients' drug costs and the latest Pearls from I.M. Peers talked about basal insulin.
https://diabetes.acponline.org/archives/2022/05/13/7.htm
13 May 2022
Once-weekly insulin had similar effects to daily insulin in type 2 diabetes, industry-funded trial finds
HbA1c levels improved by more than a point in insulin-naive patients with inadequately controlled type 2 diabetes who were randomized to a weekly 70-U dose of an investigational insulin.
https://diabetes.acponline.org/archives/2020/10/09/8.htm
9 Oct 2020
Kidney failure, CV events lower with canagliflozin than placebo, industry study finds
The trial was stopped early after an interim safety analysis found significantly better renal and cardiovascular outcomes among type 2 diabetes patients randomized to canagliflozin than those assigned to placebo.
https://diabetes.acponline.org/archives/2019/05/10/10.htm
10 May 2019
Type of insulin may affect hypoglycemia rates in older adults with type 2 diabetes, study finds
The risk of hospital visits for hypoglycemia was lower with long-acting insulin analogs versus neutral protamine Hagedorn (NPH) insulin in a retrospective study of Medicare patients.
https://diabetes.acponline.org/archives/2021/03/12/8.htm
12 Mar 2021
SGLT-2 inhibitors associated with lower risk of gout vs. GLP-1 receptor agonists
In a large, propensity-matched study, adult patients with type 2 diabetes who were newly prescribed a sodium-glucose cotransporter-2 (SGLT-2) inhibitor had a lower rate of incident gout than those newly prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist.
https://diabetes.acponline.org/archives/2020/02/14/7.htm
14 Feb 2020